CSV April 5, 2023 through April 5, 2025 All Errata for USP–NF How to use

×

How to Use

- **Searching:** Type keyword in search field at top of page. Search by all or part of a monograph title. For searches using multiple criteria, you will find items that match each of the specified criteria unless quotation marks are used.
    - For example, a search on Aminosalicylic Acid Tablets will result in anything that contains “Aminosalicyclic” OR “Acid” OR “Tablets”
    - A search for “Aminosalicylic Acid Tablets” will result in anything that specifically contains “Aminosalicylic Acid Tablets”
- **Sorting:** Click on any column header title to sort alphabetically or chronologically in ascending or descending order. Note: the page load column is sorted alphabetically so that a number is ordered by first digit vs. by the actual number; thus, numbers will not always be in order.
    - For example, page 2178 will come before page 74 on a page sort.
- **Downloading:** You can download the Errata table in Comma-separated Value (.csv). The download will include the Errata that you have filtered on.
- **Importing:**You will need to import the file into Excel or Open Office with UTF-8 encoding, as opposed to simply opening it. To import, open Excel or Open Office and select import from the File drop-down. Depending on the version you are using, you should be presented with import formatting options to include UTF-8 as one of the first steps. Importing via UTF-8 should eliminate odd character conversions.

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
POVIDONE	IM	*Second*	8778	18-Nov-2016	1-Dec-2016	*USP41–NF36*	*Second*	Line 3 of

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
	PURITIES/*Formic Acid*	*Supplement to USP39–NF34*					*Supplement to USP40–NF35*	*Sample solution*: Change column of about 80 mm to: column of about 8 mm
PLASTIC PACKAGING SYSTEMS FOR PHARMACEUTICAL USE	TEST METHODS/*Physicochemical Tests/Water Extraction/Acidity or alkalinity*	*USP39–NF34*	506	18-Nov-2016	1-Dec-2016	*USP41–NF36*	*Second Supplement to USP40–NF35*	Line 2 of *Methyl red TS 2*: Change NMT 0.1 mL of 0.02 N hydrochloric acid to: NMT 0.1 mL of 0.02 N sodium hydroxide
DESMOPRESSIN ACETATE	IDENTIFICATION/*A. Mass Spectral Analysis*	*USP39–NF34*	3387	18-Nov-2016	1-Dec-2016	*USP41–NF36*	*Second Supplement to USP40–NF35*	Line 6 of *Instrumental conditions*: Delete *Flow rate*: 0.7 mL/min *Injection volume*: 10 µL/min
SUCCINYLCHOLINE CHLORIDE	IDENTIFICATION	*USP39–NF34*	5922	18-Nov-2016	1-Dec-2016	*USP41–NF36*	*Second Supplement to USP40–NF35*	Line 1: Change It responds to *Identification*

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
INJECTION								tests *B* and *C* under *Succinylcholine Chloride*. to: *A*. The retention time of the major peak of the *Sample solution* corresponds to that of the *Standard solution*, as obtained in the *Assay*. *B*. *Thin-Layer Chromatographic Identification Test* <201> *Standard solution*: 1 mg/mL of USP Succinylcholine Chloride RS in water *Sample solution*: Nominally 1 mg/mL of succinylcholine

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								chloride from Injection in water *Chromatographic system* (See *Chromatography* <621>, *Thin-Layer Chromatography*.) *Adsorbent*: 0.25-mm layer of chromatographic silica gel *Application volume*: 1 µL *Developing solvent system*: Acetone and 1 N hydrochloric acid (1:1) *Analysis Samples*: *Standard solution* and *Sample solution* Proceed as directed in the chapter. To locate the spots, heat the

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								plate at 105° for 5 min, cool, and spray with potassium bismuth iodide TS, then heat again at 105° for 5 min. *Acceptance criteria*: Meets the requirements
MINOCYCLINE HYDROCHLORIDE EXTENDED-RELEASE TABLETS	IMPURITIES/*Organic Impurities*/*Table 6*	*First Supplement to USP39–NF34*	8101	18-Nov-2016	1-Dec-2016	*USP41–NF36*	*Second Supplement to USP40–NF35*	Footnote c: Change (4*R*,4a*S*,5a*R*,12a*S*)-4-Dimethylamino-3,10,12,12a-tetrahydroxy-7-methylamino-1,11-dioxo-1,4,4a,5,5a,6,11,12a-octahydrotetracene-2-carboxamide. to: (4*S*,4a*S*,5a*R*,12a*S*)-4-Dimethylamino-3,10,12,12a-tetrahydroxy-7-

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								methylamino-1,11-dioxo-1,4,4a,5,5a,6,11,12a-octahydrotetracene-2-carboxamide.
OMEGA-3-ACID ETHYL ESTERS CAPSULES	ASSAY/*Content of EPAee, DHAee, and Total Omega-3-Acid Ethyl Esters*	*Second Supplement to USP39–NF34*	8755	18-Nov-2016	1-Dec-2016	*USP41–NF36*	*Second Supplement to USP40–NF35*	Line 21 of *Analysis*: Change C_U = nominal concentration of the total omega-3-acid ethyl esters in the *Sample solution* (g/mL) to: C_U = Capsule fill content of the *Sample solution* (g/mL)
DUTASTERIDE	IMPURITIES/*Organic Impurities, Procedure 2*/*Table 4*	*USP40–NF35*	3924	18-Nov-2016	1-Dec-2016	*USP41–NF36*	*Second Supplement to USP40–NF35*	Footnote a: Change (5?,17?)-*N*-[2,5-Bis(trifluoromethyl)phenyl]-3-oxo-4-azaandrost-17carboxamide. to:

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								(5?,17?)-*N*-[2,5-Bis(trifluoromethyl)phenyl]-3-oxo-4-azaandrostane-17-carboxamide.
CARBIDOPA	ASSAY/ *Procedure*	*USP39–NF34*	2924	18-Nov-2016	1-Dec-2016	*USP41–NF36*	*Second Supplement to USP40–NF35*	Line 3: Change *Mobile phase*: Alcohol and 0.05 M monobasic sodium phosphate, adjusted with phosphoric acid to a pH of 2.7 (5:95) to: *Buffer*: 0.05 M monobasic sodium phosphate, adjusted with phosphoric acid to a pH of 2.7 *Mobile phase*: Alcohol and *Buffer* (5:95)
DIGOXIN TABLETS	IDENTIFICATION/*A.*	*USP39–NF34*	3494	18-Nov-2016	1-Dec-2016	*USP41–NF36*	*Second Supplement to*	Line 1 of *Procedure*:

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
							USP40–NF35	Change Proceed as directed for *Procedure* in the test for *Related glycosides* under *Digoxin*, except to omit the use of the *Gitoxin standard solution*. to: Apply 10 µL of the *Test solution* and 10 µL of the *Standard solution* on a line parallel to and about 2.5 cm from the bottom edge of a reversed-phase thin-layer chromatographic plate coated with a 0.25-mm layer of chromatographic silica

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								gel mixture to which is permanently bonded octadecylsilane (C18). Allow the spots to dry, and place the plates in a developing chamber containing a mixture of methanol and water (7:3). Develop the chromatogram until the solvent front has moved about 15 cm above the line of application. Remove the plate, and allow the solvent to evaporate. Spray the plate with *Chloramine T–trichloroacetic acid reagent*, freshly mixed,

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								and heat in an oven at 110° for 10 minutes.
STERILE PRODUCT PACKAGING?INTEGRITY EVALUATION	5. PRODUCT–PACKAGE QUALITY REQUIREMENTS AND THE MAXIMUM ALLOWABLE LEAKAGE LIMIT/*5.1 Sterility and Product Formulation Content must be Preserved; Gas Headspace Content Preservation is not Required*	*First Supplement to USP39–NF34*	7764	18-Nov-2016	1-Dec-2016	*USP41–NF36*	*Second Supplement to USP40–NF35*	Line 3 of paragraph 5: Change ultra-cold storage (<80°) to: ultra-cold storage (??80°)
CIPROFLOXACIN HYDROCHLORIDE	ADDITIONAL REQUIREMENTS/*USP Reference Standards <11>*	*Second Supplement to USP39–NF35*	8600	18-Nov-2016	1-Dec-2016	*USP41–NF36*	*Second Supplement to USP40–NF35*	Line 2 of USP Ciprofloxacin Ethylenediamine Analog RS: Change 7-(2-Aminoethylamino)-1-cyclopropyl-6-fluoro-4-oxo-1,4-dihydroquinoline-3-carb

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								oxylic acid. $C_{15}H_{16}FN_3O_3$ 305.30 to: 1-Cyclopropyl-6-fluoro-1,4-dihydro-4-oxo-7-[(2-aminoethyl)amino]-3-quinolinecarboxylic acid hydrochloride. $C_{15}H_{16}FN_3O_3 \cdot HCl$ 341.77
ROPINIROLE EXTENDED-RELEASE TABLETS	PERFORMANCE TESTS/ *Dissolution <711>/Test 1*	*Second Supplement to USP39–NF34*	8814	18-Nov-2016	1-Dec-2016	*USP41–NF36*	*Second Supplement to USP40–NF35*	Line 2 of *Buffer 1*: Adjust with *Solution A* to a pH of 4.0. to: Adjust with *Solution A* to a pH of 4.0. Dilute with water to 1 L.
AUXILIARY PACKAGING COMPONENTS	*Silica Gel/Inorganic Impurities*	*USP39–NF34*	510	18-Nov-2016	1-Dec-2016	*USP41–NF36*	*Second Supplement to USP40–NF35*	Line 1 of *Soluble ionizable salts*: Change (as $NaSO_3$): to: (as Na_2SO_4):
DIGOXIN	IDENTIFICATIO	*USP39–NF34*	3493	18-Nov-2016	1-Dec-2016	*USP41–NF36*	*Second*	Line 1 of

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
INJECTION	N/*B.*						*Supplement to USP40–NF35*	*Procedure*: Change Proceed as directed for *Procedure* in the test for *Related glycosides* under *Digoxin*, except to omit the use of the *Gitoxin standard solution*. to: Apply 10 µL of the *Test solution* and 10 µL of the *Standard solution* on a line parallel to and about 2.5 cm from the bottom edge of a reversed-phase thin-layer chromatographic plate coated with a 0.25-mm layer of chromat

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								ographic silica gel mixture to which is permanently bonded octadecylsilane (C18). Allow the spots to dry, and place the plates in a developing chamber containing a mixture of methanol and water (7:3). Develop the chromatogram until the solvent front has moved about 15 cm above the line of application. Remove the plate, and allow the solvent to evaporate. Spray the plate with *Chloramine T–trichloroaceti c acid reagent*,

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								freshly mixed, and heat in an oven at 110° for 10 minutes.
POWDERED CHASTE TREE EXTRACT	CONTAMINANTS	*USP39–NF34*	6553	18-Nov-2016	1-Dec-2016	*USP41–NF36*	*Second Supplement to USP40–NF35*	Change *Microbial Enumeration Tests <2021>*: The total bacterial count does not exceed 10^4 cfu/g. The total combined molds and yeasts count does not exceed 1000 cfu/g. It meets the requirements of the tests for absence of *Salmonella* species and *Escherichia coli*. to: *Microbial Enumeration Tests <2021>*: The total

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								bacterial count does not exceed 10^4 cfu/g. The total combined molds and yeasts count does not exceed 10^3 cfu/g. *Absence of Specified Microorganisms <2022>*: Meets the requirements of the tests for absence of *Salmonella* species and *Escherichia coli*
NAPHAZOLINE HYDROCHLORIDE	IMPURITIES/*Organic Impurities*	*First Supplement to USP39–NF34*	8105	18-Nov-2016	1-Dec-2016	*USP41–NF36*	*Second Supplement to USP40–NF35*	Line 16 of *Analysis*: Change Calculate the percentage of any individual unspecified impurity to: Calculate the

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								percentage of any other individual impurity AND Line 20 of *Analysis*: Change r_U = peak response of any individual unspecified impurity to: r_U = peak response of any other individual impurity
OMEGA-3-ACID ETHYL ESTERS CAPSULES	SPECIFIC TESTS/ *Concentration of Omega-3-Acid Ethyl Esters*	*Second Supplement to USP39–NF34*	8755	18-Nov-2016	1-Dec-2016	*USP41–NF36*	*Second Supplement to USP40–NF35*	Line 21: Change C_U = nominal concentration of the total omega-3-acid ethyl esters in the *Sample solution* (g/mL) to: C_U = Capsule fill content of the *Sample*

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								solution (g/mL)
CYCLOBENZAPRINE HYDROCHLORIDE	ADDITIONAL REQUIREMENTS/*USP Reference Standards <11>*	*USP39–NF34*	3333	18-Nov-2016	1-Dec-2016	*USP41–NF36*	*Second Supplement to USP40–NF35*	Line 2 of USP Cyclobenzaprine Related Compound B RS: Change 3-(5*H*-Dibenzo[*a*,*d*]cyclohepten-5-ylidene)-*N*-methyl-1-propanamine. $C_{19}H_{19}N$ 261.36 to: 3-(5*H*-Dibenzo[*a*,*d*]cyclohepten-5-ylidene)-*N*-methyl-1-propanamine hydrochloride. $C_{19}H_{19}N \cdot HCl$ 297.82
RIBOFLAVIN 5?-PHOSPHATE SODIUM	ASSAY/*Procedure*	*USP39–NF34*	5698	18-Nov-2016	1-Dec-2016	*USP41–NF36*	*Second Supplement to USP40–NF35*	Line 2 of *Instrumental conditions*: Change

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								Nephelometry, Turbidimetry, and Visual Comparison <855> to: *Fluorescence Spectroscopy* <853>
NORFLOXACIN	SPECIFIC TESTS/*Loss on Drying <731>*	*USP39–NF34*	5101	30-Sep-2016	1-Oct-2016	*USP41–NF36*	*First Supplement to USP40–NF35*	Line 1 of *Analysis*: Change Dry at 100° to constant weight. to: Dry under vacuum at a pressure not exceeding 5 mm of mercury at 100° to constant weight.
PROPOFOL INJECTABLE EMULSION	ADDITIONAL REQUIREMENTS/*USP Reference Standards <11>*	*USP39–NF34*	5575	30-Sep-2016	1-Oct-2016	*USP41–NF36*	*First Supplement to USP40–NF35*	Line 2 of USP Propofol Related Compound B RS: Change 2,6-Diisopropylbenzoquinone. to: 2,6-Diisopropyl

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								-1,4-benzoquinone.
HAZARDOUS DRUGS—HANDLING IN HEALTHCARE SETTINGS	*Appendix 3: Types of Biological Safety Cabinets*/Class II	*First Supplement to USP39–NF34*	7721	30-Sep-2016	1-Oct-2016	*USP41–NF36*	*First Supplement to USP40–NF35*	Line 5 of *Type A1 (formerly, Type A)*: Change radionucleotides to: radionuclides AND Line 5 of *Type A2 (formerly, Type B3)*: Change radionucleotides to: radionuclides AND Line 5 of *Type B1*: Change radionucleotides to: radionuclides AND Line 5 of *Type B2 (total exhaust)*: Change

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								radionucleotides to: radionuclides
PERINDOPRIL ERBUMINE	ADDITIONAL REQUIREMENTS/*USP Reference Standards <11>*	*First Supplement to USP39–NF34*	8127	30-Sep-2016	1-Oct-2016	*USP41–NF36*	*First Supplement to USP40–NF35*	Line 2 of USP Perindopril Related Compound A RS: Change (2*S*,3a*S*,7a*S*)-Octahydro-1*H*-indole-2-carboxylic acid hydrochloride. $C_{17}H_{28}N_2O_5 \cdot HCl$ 205.68 to: (2*S*,3a*S*,7a*S*)-Octahydro-1*H*-indole-2-carboxylic acid. $C_9H_{15}NO_2$ 169.22
CALCIUM GLUCONATE	DEFINITION	*USP39–NF34*	2879	30-Sep-2016	1-Oct-2016	*USP41–NF36*	*First Supplement to*	Line 8: Change It may contain

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
INJECTION							*USP40–NF35*	sodium hydroxide added for adjustment of the pH. to: It may contain sodium hydroxide or hydrochloric acid added for adjustment of the pH.
POTASSIUM CITRATE EXTENDED-RELEASE TABLETS	OTHER COMPONENTS/*Content of Potassium*	*USP39–NF34*	5465	30-Sep-2016	1-Oct-2016	*USP41–NF36*	*First Supplement to USP40–NF35*	Line 10 of *Analysis*: Change Result = $(C/C_U) \times [M_r/(3 \times A_r)] \times 100$ to: Result = $C \times 100/C_U$ AND Line 13 of *Analysis*: Change C_U = nominal concentration, based on the *Assay* value, of potassium

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								citrate monohydrate in the *Sample solution* (µg/mL) M_r = molecular weight of potassium citrate monohydrate, 324.41 A_r = atomic weight of potassium, 39.10 to: C_U = concentration of potassium citrate anhydrous ($C_6H_5K_3O_7$) in the *Sample solution* calculated from the *Assay* value of potassium citrate monohydrate ($C_6H_5K_3O_7 \cdot H_2O$) (µg/mL)
ST. JOHN'S	SPECIFIC	*USP39–NF34*	6817	30-Sep-2016	1-Oct-2016	*USP41–NF36*	*First*	Insert missing

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
WORT	TESTS						*Supplement to USP40–NF35*	test: *Articles of Botanical Origin <561>, Methods of Analysis, Total Ash:* NMT 5.0%
OXYMETAZOLINE HYDROCHLORIDE	IMPURITIES/*Organic Impurities*/*Table 2*	*First Supplement to USP39–NF34*	8116	30-Sep-2016	1-Oct-2016	*USP41–NF36*	*First Supplement to USP40–NF35*	Row 2 of Column 1: Change Oxymetazoline related compound A to: Oxymetazoline related compound A[a] AND Add footnote a: *N*-(2-Aminoethyl)-2-[4-(*tert*-butyl)-3-hydroxy-2,6-dimethylphenyl]acetamide.
ANALYTICAL DATA—INTERPRETATION AND TREATMENT	APPENDIX C: EXAMPLES OF OUTLIER TESTS FOR ANALYTICAL	*USP39–NF34*	767	30-Sep-2016	1-Oct-2016	*USP41–NF36*	*First Supplement to USP40–NF35*	Row 13 of Column 4 of *Table 5. Test Results of Re-Applied*

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
	DATA/*Hampel's Rule*							*Hampel's Rule*: Change 0.14 to: 0.15
PARICALCITOL INJECTION	IMPURITIES/*Organic Impurities/ Chromatographic system/ Columns*	*USP39–NF34*	5279	30-Sep-2016	1-Oct-2016	*USP41–NF36*	*First Supplement to USP40–NF35*	Line 1 of *Guard*: Change 4.6-mm × 7.5-mm; packing L1 to: 4.6-mm × 7.5-mm or 4.6-mm × 10-mm; packing L1
TRAVOPROST OPHTHALMIC SOLUTION	ADDITIONAL REQUIREMENTS/*USP Reference Standards <11>*	*USP39–NF34*	6226	30-Sep-2016	1-Oct-2016	*USP41–NF36*	*First Supplement to USP40–NF35*	Line 2 of USP Travoprost Related Compound A RS: Change (5*Z*,13*E*)-(9*S*,11*R*,15*R*)-9,11,15-Trihydroxy-16-(*m*-trifluoromethylphenoxy)-17,18,19,20-tetranor-5,13-prostadienoic acid.

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								to: (5*Z*,13*E*)-(9*S*,11*R*,15*R*)-9,11,15-Trihydroxy-16-(*m*-trifluoromethylphenoxy)-17,18,19,20-tetranor-5,13-prostadienoic acid or (*Z*)-7-((1*R*,2*R*,3*R*,5*S*)-3,5-Dihydroxy-2-{(*R*,*E*)-3-hydroxy-4-[3-(trifluoromethyl)phenoxy]but-1-enyl}cyclopentyl)hept-5-enoic acid.
DANTROLENE SODIUM	IDENTIFICATION/*D.*	*First Supplement to USP39–NF34*	8035	30-Sep-2016	1-Oct-2016	*USP41–NF36*	*First Supplement to USP40–NF35*	Line 2 of *Solution A*: Change tetramethylammonium hydroxide solution to: tetramethylam

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								monium hydroxide TS
PERINDOPRIL ERBUMINE	IMPURITIES/*Organic Impurities*/*Table 2*	*First Supplement to USP39–NF34*	8127	30-Sep-2016	1-Oct-2016	*USP41–NF36*	*First Supplement to USP40–NF35*	Line 2 of footnote g: Change ocatahydro to: octahydro
FLUORESCEIN SODIUM	ASSAY/*Procedure*	*USP39–NF34*	3960	30-Sep-2016	1-Oct-2016	*USP41–NF36*	*First Supplement to USP40–NF35*	Line 3 of *Standard stock solution*: Change 1.0 mg/mL of fluorescein sodium in *Diluent* is prepared as follows. to: 1.0 mg/mL of fluorescein sodium is prepared as follows.
PROPOFOL	ADDITIONAL REQUIREMENTS/*USP Reference Standards <11>*	*USP39–NF34*	5573	30-Sep-2016	1-Oct-2016	*USP41–NF36*	*First Supplement to USP40–NF35*	Line 2 of USP Propofol Related Compound B RS: Change 2,6-Diisopropylbenzoquinone.

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								to: 2,6-Diisopropyl-1,4-benzoquinone.
HAZARDOUS DRUGS—HANDLING IN HEALTHCARE SETTINGS	REFERENCES	*First Supplement to USP39–NF34*	7721	30-Sep-2016	1-Oct-2016	*USP41–NF36*	*First Supplement to USP40–NF35*	Line 2 of first reference: Delete http://www.acoem.org/Reproductive_Developmental_Hazard_Management.aspx. AND Line 2 of second reference: Delete http://www.asco.org/advocacy/worker-safety-when-handling-hazardous-drugs-focus-statement-oncology-societies.
PERINDOPRIL ERBUMINE	CHEMICAL INFORMATION	*First Supplement to USP39–NF34*	8127	30-Sep-2016	1-Oct-2016	*USP41–NF36*	*First Supplement to USP40–NF35*	Line 9: Delete (2*S*,3a*S*,7a*S*)-1-{(*S*)-2-[(*R*)-1-Ethoxy-1-oxopentan-2-ylami

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								no]propanoyl}octahydro-1*H*-indole-2-carboxylic acid
CALCIUM GLUCONATE	CHEMICAL INFORMATION	*USP39–NF34*	2877	30-Sep-2016	1-Oct-2016	*USP41–NF36*	*First Supplement to USP40–NF35*	Line 5: Change [18016-24-5]. to: [66905-23-5].
PHENYTOIN SODIUM	IDENTIFICATION/*B. Identification Tests—General, Sodium <191>*	*USP39–NF34*	5388	30-Sep-2016	1-Oct-2016	*USP41–NF36*	*First Supplement to USP40–NF35*	Line 2: Change tetramethylammonium hydroxide solution, to: tetramethylammonium hydroxide TS,
VITAMIN A ORAL LIQUID PREPARATION	ASSAY/*Vitamin A*	*USP39–NF34*	6374	30-Sep-2016	1-Oct-2016	*USP41–NF36*	*First Supplement to USP40–NF35*	Line 7 of *Analysis*: Change Result = $(r_U/r_S) \times (C/W) \times (V/D) \times U \times (100/L)$ to: Result = $(r_U/r_S) \times (C/W) \times D \times U \times (100/L)$ AND Line 16 of the *Analysis*: Delete

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								V = volume of the *Sample solution* (mL)
OXYMETAZOLINE HYDROCHLORIDE	ADDITIONAL REQUIREMENTS/*USP Reference Standards <11>*	*First Supplement to USP39–NF34*	8116	30-Sep-2016	1-Oct-2016	*USP41–NF36*	*First Supplement to USP40–NF35*	USP Oxymetazoline Related Compound A RS: Change *N*-(2-Aminoethyl)-2-[4-(*tert*-butyl)-3-hydroxy-2,6-dimethylphenyl]acetamide. $C_{16}H_{26}N_2O_2$ 278.39 to: *N*-(2-Aminoethyl)-2-[4-(*tert*-butyl)-3-hydroxy-2,6-dimethylphenyl]acetamide hydrochloride. $C_{16}H_{26}N_2O_2 \cdot HCl$ 314.85
DESLORATADINE	ADDITIONAL REQUIREMENTS/*USP Reference*	*Second Supplement to USP39–NF34*	8607	30-Sep-2016	1-Oct-2016	*USP41–NF36*	*First Supplement to USP40–NF35*	Line 2 of USP Desloratadine Related Compound B

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
	Standards <11>							RS: Change 8-Chloro-11-(1,2,3,6-tetrahydropyridin-4-yl)-6,11-dihydro-5*H*-benzo[5,6]cyclohepta[1,2-*b*]pyridine. $C_{19}H_{19}ClN_2$ 310.82 to: 8-Chloro-11-(1,2,3,6-tetrahydropyridin-4-yl)-6,11-dihydro-5*H*-benzo[5,6]cyclohepta[1,2-*b*]pyridine hydrochloride. $C_{19}H_{20}Cl_2N_2$ 347.28
EXTRACTABLES ASSOCIATED WITH PHARMACEUTICAL PACKAGING	REFERENCES	*USP39–NF34*	1835	29-Jul-2016	1-Aug-2016	*USP41–NF36*	*First Supplement to USP40–NF35*	Delete references 5, 7, 9, and 12.

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
SYSTEMS								
FLUORESCEIN SODIUM	IMPURITIES/*Organic Impurities*	*USP39–NF34*	3960	29-Jul-2016	1-Aug-2016	*USP41–NF36*	*First Supplement to USP40–NF35*	Row 7 of column 1 of *Table 2*: Change Total impurities to: Total unspecified impurities
HALOPERIDOL DECANOATE	IMPURITIES/*Organic Impurities*/*Table 2*	*USP39–NF34*	4184	29-Jul-2016	1-Aug-2016	*USP41–NF36*	*First Supplement to USP40–NF35*	Footnote k: Change 4-(4?-Chlorobiphenyl-4-yl)-1-[4-(4-fluorophenyl)-4-oxobutyl]piperidin-4-yl decanoate. to: 4-(3?-Chlorobiphenyl-4-yl)-1-[4-(4-fluorophenyl)-4-oxobutyl]piperidin-4-yl decanoate. AND Footnote l: Change 4-(3?-Chlorobiphenyl-4-yl)-1-[4-(4-fluorophenyl)

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								-4-oxobutyl]piperidin-4-yl decanoate. to: 4-(4?-Chlorobiphenyl-4-yl)-1-[4-(4-fluorophenyl)-4-oxobutyl]piperidin-4-yl decanoate.
RIZATRIPTAN BENZOATE TABLETS	PERFORMANCE TESTS/ *Dissolution <711>*/ *Chromatographic procedure*	*USP39–NF34*	5750	29-Jul-2016	1-Aug-2016	*USP41–NF36*	*First Supplement to USP40–NF35*	Add *Buffer*: 1.36 g/L of monobasic potassium phosphate. Adjust the pH of the solution with phosphoric acid to 2.5.
TRIHEXYPHENIDYL HYDROCHLORIDE ORAL SOLUTION	*Assay*	*USP39–NF34*	6266	29-Jul-2016	1-Aug-2016	*USP41–NF36*	*First Supplement to USP40–NF35*	Line 1 of *Mobile phase* and *Chromatographic system*: Change Prepare as directed in the *Assay* under *Trihexyphenidyl Hydrochloride*. to: *Mobile*

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								phase—Prepare a mixture of acetonitrile, water, and triethylamine (920:80:0.2), adjust with phosphoric acid to a pH of 4.0, mix, filter, and degas. Make adjustments if necessary (see *System Suitability* under *Chromatography* <621>). *Chromatographic system* (see *Chromatography* <621>)—The liquid chromatograph is equipped with a 210-nm detector and a 4.6-mm × 8-cm column that contains 3-µm packing L1. The flow rate is

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								about 2 mL per minute. Chromatograph the *Standard preparation*, and record the peak responses as directed for *Procedure*: the column efficiency determined from the analyte peak is not less than 1300 theoretical plates, the tailing factor for the analyte peak is not more than 3.0, and the relative standard deviation for replicate injections is not more than 1.0%. AND Line 1 of *Procedure*:

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								Change Proceed as directed for *Procedure* in the *Assay* under *Trihexyphenidyl Hydrochloride*. to: Separately inject equal volumes (about 10 µL) of the *Standard preparation* and the *Assay preparation* into the chromatograph, record the chromatograms, and measure the responses for the major peaks. AND Line 7 of *Procedure*: Change and the other terms are as defined therein.

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								to: *C* is the concentration, in mg per mL, of USP Trihexyphenidyl Hydrochloride RS in the *Standard preparation*, r_U and r_S are the trihexyphenidyl peak responses obtained from the *Assay preparation* and the *Standard preparation*, respectively.
SULINDAC TABLETS	IM PUR ITIES/*Organic Impurities*	*First Supplement to USP39–NF34*	8160	29-Jul-2016	1-Aug-2016	*USP41–NF36*	*First Supplement to USP40–NF35*	Line 1 of *System suitability*/*Relative standard deviation*: Change NMT 2.0% for any peak to: NMT 2.0% for sulindac,

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								sulindac related compound B, and sulindac related compound C AND Line 3 of *Analysis*: Change Calculate the percentage of the labeled amount of sulindac related compound A, sulindac related compound B, or sulindac related compound C in the portion of Tablets taken: to: Calculate the percentage of sulindac related compound B or sulindac related compound C in the portion of Tablets taken: AND

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								Line 8 of *Analysis*: Change r_U = peak response of sulindac related compound A, sulindac related compound B, or sulindac related compound C from the *Sample solution* to: r_U = peak response of sulindac related compound B or sulindac related compound C from the *Sample solution* AND Line 12 of *Analysis*: Change r_S = peak response of sulindac related compound A, sulindac related

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								compound B, or sulindac related compound C from the *Standard solution* to: r_S = peak response of sulindac related compound B or sulindac related compound C from the *Standard solution*
FELBAMATE ORAL SUSPENSION	PERFORMANCE TESTS/ *Dissolution <711>*	*USP39–NF34*	3855	29-Jul-2016	1-Aug-2016	*USP41–NF36*	*First Supplement to USP40–NF35*	Line 4 of *System suitability*: Change [Note—The relative retention times for methylparaben and felbamate are about 0.5 and 1.0, respectively.] to: [Note—The

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								relative retention times for felbamate and methylparaben are about 1.0 and 1.5, respectively.]
GRANISETRON HYDROCHLORIDE TABLETS	*USP Reference standards <11>*	*USP39–NF34*	4155	29-Jul-2016	1-Aug-2016	*USP41–NF36*	*First Supplement to USP40–NF35*	Line 2 of USP Granisetron Related Compound B RS: Change (*N*-[(1*R*,3*r*,5)-9-Methyl-9-azabicyclo[3.3.1]non-3-yl]-1*H*-indazole-3-carboxamide). to: *N*-[(1*R*,3*r*,5*S*)-9-Methyl-9-azabicyclo[3.3.1]non-3-yl]-1*H*-indazole-3-carboxamide.
NAPROXEN TABLETS	ASSAY/*Procedure*/*System*	*USP39–NF34*	4993	29-Jul-2016	1-Aug-2016	*USP41–NF36*	*First Supplement to USP40–NF35*	Line 1 of *Tailing factor*: Change NLT 2.0

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
	suitability/Suitability requirements							to: NMT 2.0

Pagination

- First page « First
- Previous page ‹ Previous
- …
- Page 21
- Page 22
- Page 23
- Page 24
- Page 25
- Page 26
- Page 27
- Page 28
- Page 29
- …
- Next page Next ›
- Last page Last »